Tonix Pharmaceuticals reported a 37% increase in Q3 2026 net sales of TONMYA, reaching approximately $15 million, driven by expanded payer access and a larger sales force. The company holds $163 million in cash and is advancing clinical trials for treatments in major depressive disorder, Lyme disease prevention, and kidney transplant rejection. Despite increased R&D and marketing expenses leading to a net loss of $53.3 million, Tonix remains focused on growth and pipeline development. A conference call was held to discuss these results and future plans.
Tonix Pharmaceuticals' Q3 2026 financial results and operational highlights provide context for readers. As of Nov 09, 2026 18:41 WIB, among 150 priced Health-sector US stocks tradable on Pluang, 108 rose and 26 fell. Notable movers include TG Therapeutics Inc (TGTX) at USD 63.00 with a 1-day change of +5.31%, Guardant Health Inc. (GH) at USD 157.76 up 4.57%, and ClearPoint Neuro Inc (CLPT) at USD 8.99 with a 4.53% increase, with TGTX showing the highest single-day gain.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
